IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a note issued to investors on Tuesday, May 7th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.59) for the quarter, down from their prior forecast of ($0.57). Leerink Partnrs currently has a "Outperform" rating on the stock. The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($2.26) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences' Q3 2024 earnings at ($0.64) EPS, Q4 2024 earnings at ($0.70) EPS, FY2024 earnings at ($2.62) EPS, FY2025 earnings at ($3.18) EPS, FY2026 earnings at ($3.29) EPS, FY2027 earnings at ($2.46) EPS and FY2028 earnings at $1.17 EPS.
A number of other analysts also recently issued reports on the company. Capital One Financial reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Thursday, February 22nd. Royal Bank of Canada increased their price target on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the company an "outperform" rating in a research note on Wednesday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. BTIG Research initiated coverage on IDEAYA Biosciences in a research report on Friday, March 8th. They issued a "buy" rating and a $55.00 price objective for the company. Finally, Citigroup raised their target price on IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, March 21st. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $47.50.
Read Our Latest Report on IDEAYA Biosciences
IDEAYA Biosciences Price Performance
IDYA traded up $0.53 on Friday, reaching $41.17. 446,904 shares of the company's stock were exchanged, compared to its average volume of 825,619. The stock has a market cap of $3.08 billion, a PE ratio of -20.04 and a beta of 0.83. IDEAYA Biosciences has a twelve month low of $20.68 and a twelve month high of $47.74. The stock's fifty day moving average price is $42.49 and its 200-day moving average price is $38.42.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. IDEAYA Biosciences's revenue was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.49) EPS.
Institutional Trading of IDEAYA Biosciences
Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its stake in IDEAYA Biosciences by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,474 shares of the company's stock worth $40,000 after purchasing an additional 723 shares in the last quarter. JTC Employer Solutions Trustee Ltd acquired a new position in shares of IDEAYA Biosciences during the first quarter worth about $67,000. AJOVista LLC purchased a new stake in shares of IDEAYA Biosciences during the fourth quarter worth approximately $99,000. SG Americas Securities LLC acquired a new stake in IDEAYA Biosciences in the first quarter valued at approximately $101,000. Finally, Exchange Traded Concepts LLC raised its holdings in IDEAYA Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company's stock valued at $171,000 after acquiring an additional 1,219 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.
About IDEAYA Biosciences
(
Get Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
See Also
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
